Barclays
HTGM

Barclays’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Barclays’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14
Closed -$13K – 7502
2018
Q3 		$13K Buy
+14
New +$9.24K ﹤0.01% 6597
2018
Q2 		– Sell
-27
Closed -$18K – 7415
2018
Q1 		$18K Buy
+27
New +$20.3K ﹤0.01% 6477
2017
Q2 		– Sell
-15
Closed -$19K – 7043
2017
Q1 		$19K Buy
+15
New +$7.22K ﹤0.01% 5836

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Barclays's HTGM Position: Q4 2018 in Review

Barclays sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2018, closing a stake of 14 shares — an estimated $13K sold.

Barclays first reported a position in HTGM in Q1 2017 and held it in 3 quarters. The position peaked at $19K in Q1 2017. 48 funds tracked by Wall St. Rank hold HTGM as of Q4 2018.

  • Barclays reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Barclays sold 14 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2018, an estimated $13K.
  • Barclays first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Barclays's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $19K in Q1 2017.
  • 48 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2018.

Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.